Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors

被引:27
作者
Bronner, S
Jehl, F
Peter, JD
Ploy, MC
Renault, C
Arvis, P
Monteil, H
Prevost, G
机构
[1] Univ Strasbourg 1, Inst Bacteriol, Fac Med, Hop Univ Strasbourg, F-67000 Strasbourg, France
[2] CHU Dupuytren, Dept Microbiol, F-87042 Limoges, France
[3] Bayer Pharma, F-92807 Puteaux La Defense, France
关键词
D O I
10.1128/AAC.47.5.1621-1629.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Bacterial endophthalmitis is a serious complication of ocular surgery and of eye trauma; the leading causative organisms are Staphylococcus aureus strains. Tissue damage is due both to the host inflammatory response and to toxin synthesis by bacteria. Systemic treatment remains difficult because most antibiotics show poor ocular penetration. Moxifloxacin (MXF), a novel fluoroquinolone, was evaluated for its penetration into the vitreous of normal rabbit eyes and of eyes of rabbits infected for 24 h with methicillin-susceptible and methicillin-resistant S. aureus (MSSA and MRSA) following a single intravenous administration of 5 or 20 mg/kg. MXF penetration was rapid and efficient regardless of the dose, ranging from 28 to 52%. An inflammatory state of the vitreous significantly increased penetration after the 20-mg/kg dose, with penetration reaching 52%. Concentrations determined in the vitreous cavity following a 20-mg/kg administration showed a 3.5-fold decrease of the bacterial density within 5 h for MSSA (MIC, 0.125 mug/ml) and a 1.6-fold decrease for MRSA (MIC, 4 mug/ml) strains, respectively. By using a semiquantitative reverse transcription-PCR method, the expression of luk-PV and hlgCB, but not hlgA, encoding staphylococcal leukotoxins, was detected in the vitreous without MXF treatment. A slight decrease in the expression of leucotoxins and sarA, agr, and sigB virulence regulatory factors was observed 1 h following the administration of 5 mg of MXF per kg.
引用
收藏
页码:1621 / 1629
页数:9
相关论文
共 46 条
[41]   Moxifloxacin in the therapy of experimental pneumococcal meningitis [J].
Schmidt, H ;
Dalhoff, A ;
Stuertz, K ;
Trostdorf, F ;
Chen, V ;
Schneider, O ;
Kohlsdorfer, C ;
Brück, W ;
Nau, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1397-1401
[42]  
SIQUIRA JA, 1997, J MED MICROBIOL, V46, P1
[43]   Fluoroquinolones - Place in ocular therapy [J].
Smith, A ;
Pennefather, PM ;
Kaye, SB ;
Hart, CA .
DRUGS, 2001, 61 (06) :747-761
[44]   Assessment of the role of gamma-toxin in experimental endophthalmitis using a hlg-deficient mutant of Staphylococcus aureus [J].
Supersac, G ;
Piémont, Y ;
Kubina, M ;
Prévost, G ;
Foster, TJ .
MICROBIAL PATHOGENESIS, 1998, 24 (04) :241-251
[45]   Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration [J].
Wise, R ;
Andrews, JM ;
Marshall, G ;
Hartman, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1508-1510
[46]   Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo [J].
Worlitzsch, D ;
Kaygin, H ;
Steinhuber, A ;
Dalhoff, A ;
Botzenhart, K ;
Döring, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :196-202